Phase 2 N=27 Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Cervical Cancer
Primary: Anti-tumor Activity as Measured by Surviving Progression-free — 59 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Number of Patients With Dose-limiting Toxicities, as Assessed by CTCAE v 4.0 — 0 Participants
Phase 2 N=38 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Squamous Cell Carcinoma · Recurrent Cervical Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants
Phase 2 N=29 A Trial for Patients With Advanced/Recurrent Cervical Cancer
Cervical Intraepithelial Neoplasia · Uterine Neoplasms · Genital Neoplasms, Female
Primary: Tumor Response — 0; 4; 16; 7 participants
Phase 2 N=50 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Cervical Squamous Cell Carcinoma · Recurrent Cervical Cancer
Primary: Progression-free Survival Greater Than 6 Months — 23.9 percentage of participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=11 Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Number of Participants With Objective Response Rate (ORR, Either Partial or Complete Response) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version…
Phase 2 N=27 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
Cervical Cancer
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 0; 0 participants
Phase 2 N=76 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Tumor Response — 1; 7; 17; 34 participants
Phase 2 N=37 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Small Cell Carcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 10; 0 participants
Phase 2 N=27 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Small Cell Carcinoma
Primary: Tumor Response — 7.4 percentage of participants
Phase 2 N=42 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Human Papillomavirus Infection
Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events
Phase 2 N=32 Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
Recurrent Cervical Cancer · Stage IIIA Cervical Cancer · Stage IIIB Cervical Cancer
Primary: Progression-free Survival — 2.5 Months
Phase 3 N=452 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Overall Survival — 14.26; 17.51; 12.68; 16.20 months
Phase 2 N=35 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma
Primary: Overall Objective Response Rate (CR+PR) — 2; 5; 8 participants
Phase 2 N=31 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Objective Tumor Response — 0.071 proportion
Phase 2 N=55 Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants
Phase 2 N=37 Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Phase 1 N=12 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Effects of Immunotherapy · Metastatic/Recurrent Cervical Cancer · Cervical Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants
Phase 3 N=340 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Recurrence-free Survival (RFS) Rate at 3-years — 85.4; 88.5 percentage of participants — p=0.0927
Phase 2 N=41 Irinotecan Study For Cervical Cancer
Uterine Cervical Neoplasms
Primary: Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population) — 8; 7; 11; 6 participant
Phase 3 N=608 Study of Cemiplimab in Adults With Cervical Cancer
Squamous Cell Carcinoma (SCC) · Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Primary: Overall Survival (OS) — 11.7; 8.5 Months — p=<0.00001
Phase 2 N=113 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Cervical Cancer
Primary: Objective Response Rate (ORR) — 17.7 Percentage of Participants
N/A N=12 Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Phase 3 N=502 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
Primary: Overall Survival — 11.5; 9.5 Months — p=0.0038
Phase 2 N=70 Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma · Recurrent Ovarian Carcinoma · Stage IV Ovarian Cancer
Primary: Median Time to Progression — 7.2 months
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 2 N=118 A Study LY2228820 for Recurrent Ovarian Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Phase 2 N=33 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Phase 2 N=29 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients